Johnson & Johnson (J&J) has announced that Fortive Corp has made an offer of about $2.7 billion in cash for its Advanced Sterilisation Products (ASP) business.
Hemlibra threatens to take market share from Advate
Takeda aiming for $1.4bn savings per year
Express Scripts’ Miller backs “responsible” price
CEO wants “broad nerve block label” for Exparel
But deal with Samsung prevents US launch until mid-2023
Focus on services, not products, report argues.
GSK is left as sole bidder amid speculation that the sale is off.
Mundipharma’s third biosimilar tie-up with Celltrion
Proposals also include fresh attack on drug prices
AstraZeneca’s biologics division MedImmune is to spin out a new standalone biotech to develop six early-stage inflammation and autoimmunity programmes.